Episode 24: A Between the Biotech Waves conversation with John Hoffman, managing director & head of healthcare equity capital markets at Credit Suisse
Between the Biotech Waves
00:00
The Importance of Preparing for a Triangle IPO
It feels like from the private side people now have looked at portfolios. They've kind of rejigged their overall capital allocations or reserves under the assumption that they're holding these companies longer. So it does I agree with you it does feel that now is people will start putting this capital to work. It feels though for earlier stage sort of a seed A and maybe B versus BC and mez, so I wonder in 23 how we're going to see some of the valuations for the private companies effectively reset ever.
Play episode from 33:25
Transcript
